Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
暂无分享,去创建一个
T. Dick | N. Ma | T. Keller | David Beer | V. Dartois | J. Knox | J. Jiricek | A. Goh | M. Cynamon | E. Schmitt | P. Krastel | F. Petersen | V. Sambandamurthy | B. L. Suresh | Mekonnen Kurabachew | S. H. Lu
[1] A. Matteelli,et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control , 2007, Expert review of anti-infective therapy.
[2] I. Chopra,et al. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. , 2007, Current opinion in investigational drugs.
[3] L. Bastide,et al. Progress in targeting bacterial transcription. , 2007, Drug discovery today.
[4] Alan P. Johnson. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. , 2007, Current opinion in investigational drugs.
[5] Mehran Hosseini,et al. Global incidence of multidrug-resistant tuberculosis. , 2006, The Journal of infectious diseases.
[6] L. Bastide,et al. Mutation in the Bacillus subtilis RNA Polymerase β′ Subunit Confers Resistance to Lipiarmycin , 2006, Antimicrobial Agents and Chemotherapy.
[7] H. Floss,et al. Rifamycin — Mode of Action, Resistance, and Biosynthesis , 2005 .
[8] P. Appelbaum,et al. Activity of OPT-80, a Novel Macrocycle, Compared with Those of Eight Other Agents against Selected Anaerobic Species , 2004, Antimicrobial Agents and Chemotherapy.
[9] F. Monti,et al. Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. , 2004, European journal of biochemistry.
[10] R. Sandaa,et al. A multiplex polymerase chain reaction assay for genus-, group- and species-specific detection of mycobacteria. , 2004, Diagnostic microbiology and infectious disease.
[11] D. Mitchison,et al. The search for new sterilizing anti-tuberculosis drugs. , 2004, Frontiers in bioscience : a journal and virtual library.
[12] D. Andersson,et al. Effect of rpoB Mutations Conferring Rifampin Resistance on Fitness of Mycobacterium tuberculosis , 2004, Antimicrobial Agents and Chemotherapy.
[13] C. Çavuşoğlu,et al. Characterization of rpoB Mutations in Rifampin-Resistant Clinical Isolates of Mycobacterium tuberculosis from Turkey by DNA Sequencing and Line Probe Assay , 2002, Journal of Clinical Microbiology.
[14] E. Chan,et al. Current medical treatment for tuberculosis , 2002, BMJ : British Medical Journal.
[15] S. Yokoyama,et al. Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 Å resolution , 2002, Nature.
[16] C. Fishwick,et al. RNA Polymerase Inhibitors with Activity against Rifampin-Resistant Mutants of Staphylococcus aureus , 2000, Antimicrobial Agents and Chemotherapy.
[17] Strohl,et al. The role of natural products in a modern drug discovery program. , 2000, Drug discovery today.
[18] W. Jacobs,et al. New use of BCG for recombinant vaccines , 1991, Nature.
[19] J. McAlpine,et al. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. , 1987, The Journal of antibiotics.
[20] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[21] A. Sonenshein,et al. Initiation of transcription in vitro inhibited by lipiarmycin. , 1979, Journal of molecular biology.
[22] G. Lancini,et al. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. , 1975, The Journal of antibiotics.
[23] F. Parenti,et al. LIPIARMYCIN, A NEW ANTIBIOTIC FROM ACTINOPLANES , 1975 .
[24] Mark S Butler,et al. Natural products to drugs: natural product derived compounds in clinical trials. , 2005, Natural product reports.
[25] C. Dye,et al. Global tuberculosis control: surveillance planning financing. WHO report 2003. , 2003 .
[26] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[27] P. Howse,et al. Isolation and structure determination , 1998 .